Drug development company Sareum Holdings Plc (LON:SAR) reported that Sierra Oncology Inc (NASDAQ:SRRA), the licence holder advancing clinical cancer candidate SRA737, announced that it has significantly expanded’ its clinical development programme.
Sierra Holdings has announced ‘noteworthy progresses’ in the Dose Escalation Phase 1 portions for both of its ongoing Phase I/II clinical trials involving Chk1 inhibitor, SRA737.
Sareum Holdings: Pre-clinical data for new cancer combination to be presented to US peers
Phase 2 portions of both trials (efficacy) will be expanded to approximately 200 patients across ten cancer indications.
Sierra has also announced it is planning to initiate a Phase 1b/2 clinical trial in the fourth quarter of 2018 that will evaluate SRA737 in combination with ZEJULA (niraparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Sierra Oncology holds exclusive and worldwide right for the Chk1 inhibitor, SRA737, which it licensed from the CRT Pioneer Fund, a partner of Sareum, in September 2016.